The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
GWMO is now in the best place it has been since it's inception. The work has been done and all that is left is proving up a resource. If the resource is there it's a big win. If not the current BOD have done all they can and the tailings will protect our investments short term. Best risk reward balance out there imo.
Not sure what you were expecting with nothing at phase 3? I think a lot of investors were unrealistic here sadly. It's a long term winner but have you got the cash flow to hold?
It's a pharma company. If you expected gains overnight, over a month, over a year even, you're investing in the wrong thing
Or hold until dilution makes profit impossible
It's all coming to a head now.
If (when) they get a product to market we'll see a fair price. I'll be holding until then.
Pardon me? Coming through!
I asked this question directly during the zoom meeting. This is why he dodged it.
Jenn i'm not sure if this is meant to be sarcasm? I'm going to say yes otherwise I shan't reply.
What a fantastic resilience after an shock placing. It would appear the faith remains in the acreage in Nevada. One strike is all it takes to make it and the more ground you cover the more chance you have. Holding for gold
Sadly still some covid chasers around. Not long now before Q2 and the next phase of our pipeline.
Consolidation means nothing really. Share price is also irrelevant funnily enough. MCAP Vs your perceived value is the real marker!
Phase III is all that matters. All of the other posts before then are like farting in a hurricane
All just noise while I wait for phase III
Baffling sometimes SK. It would seem the posters on this board believe, I mean GENUINELY BELIEVE, that a company like TILS will be bringing in a product overnight. A reflection on the current populations need for instant gratification. Doc K gives all these interviews on the technology repeating the same thing, not as a "rehash" as some say, but more as a hope that everyone will actually listen to what is said and consider what that means scientifically. Commercialisation is great and obviously required but not until phase III is well underway or even concluded. Honestly baffled. And they'll say $250m cash raise option at minimum (that's right MINIMUM) £1.50 a share doesn't ooze confidence. I need to stop reading this board as it winds me up!
Felt like he couldn't say too much on the possibility of fast track!
As long as a marketable product appears over the next 3 years it doesn't really matter IMO
Read the relevant RNS
Read the relevant RNS
Well said. Couldn't agree more on the derisked nature especially for those of us who also hold AccuStem entitlement. Will come good long term.